Atossa Genetics' Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density

Stock Information for Atossa Genetics Inc.

Loading

Please wait while we load your information from QuoteMedia.